mani
factor
influenc
choic
method
use
develop
antibodi
infecti
agent
paper
review
current
statu
main
technolog
use
produc
monoclon
antibodi
mab
b
cell
antigensensit
anim
compani
adopt
advanc
highthroughput
method
major
technolog
use
veterinari
medic
research
laboratori
classic
hybridoma
fusion
recombin
librari
select
techniqu
method
inher
advantag
limit
mani
common
aspect
use
immun
rodent
laboratori
expertis
method
antibodi
develop
distinct
advantag
abil
advanc
mab
technolog
new
reemerg
infecti
threat
world
emphas
need
qualiti
immunoreag
need
maintain
expertis
mab
develop
provid
exampl
common
applic
mab
reagent
use
identifi
pathogen
sarscoronaviru
sarscov
bacillu
anthraci
footandmouth
diseas
fmd
viru
also
outlin
framework
investig
make
ration
decis
concern
method
use
develop
mab
base
upon
characterist
pathogen
studi
intend
downstream
applic
lastli
provid
paramet
immunis
mice
classif
system
describ
expect
outcom
mab
develop
strategi
use
class
immunogen
gener
mab
desir
activ
crown
abbrevi
mab
monoclon
antibodi
sarscov
sever
acut
respiratori
syndrom
coronaviru
fmd
viru
footandmouth
diseas
viru
pa
protect
antigen
bacillu
anthraci
bsa
bovin
serum
albumin
fb
fetal
bovin
serum
hat
hypoxanthineaminopterinthymidin
scfv
singl
chain
variabl
fragment
fab
fragment
respons
antigen
bind
pbl
peripher
blood
leucocyt
viral
protein
viral
protein
fmd
viru
iem
immunoelectron
microscopi
ihc
immunohistochemistri
ifa
immunoflouresc
vgene
immunoglobulin
variabl
region
gene
respons
encod
antigen
contact
domain
abil
produc
monoclon
antibodi
mab
essenti
infecti
pathogen
product
recogn
one
signific
inaugur
scientif
accomplish
biotechnolog
uniform
characterist
mab
critic
research
develop
work
vastli
improv
sensit
specif
diagnost
assay
antibodi
reagent
provid
basi
larg
number
highli
specif
reproduc
immunoassay
rapid
diagnosi
infecti
diseas
review
payn
et
al
andreotti
et
al
mab
expect
earlyon
replac
immunolog
assay
base
older
technolog
complement
fixat
polyclon
serolog
similarli
highspecif
mab
produc
vitro
make
mab
cocktail
ideal
fullydefinedtherapeut
antibodi
prepar
characterist
mab
rapidli
creat
expand
role
reagent
vaccin
research
develop
therapi
clinic
diagnosi
clear
reason
mab
yet
becom
magic
bullet
first
hope
recent
advanc
transgen
mice
may
help
realis
goal
bioterror
emerg
infecti
diseas
need
solv
entir
genom
full
protein
guarante
futur
need
highqual
mab
enter
modern
era
proteom
inde
mab
view
key
reagent
solv
gap
genom
proteom
requir
highthroughput
adapt
techniqu
outlin
review
gavilondo
larrick
major
focu
direct
interplay
host
antibodi
molecul
pathogen
toxin
make
particular
use
highcontain
emerg
pathogen
greatest
potenti
disrupt
trade
caus
outbreak
human
andor
use
bioterrorist
event
pathogen
develop
mab
laboratori
includ
sarscov
fmd
viru
exotoxin
bacillu
anthraci
mycoplasma
speci
neisseria
meningitidi
capsular
polysaccharid
detail
studi
perform
sarscov
patoxin
protect
antigen
fmd
viru
pathogen
repres
differ
type
infecti
organ
exampl
sarscov
bacillu
anthraci
viral
bacteri
pathogen
respect
capabl
caus
acut
diseas
also
anim
reservoir
howev
former
newli
emerg
infecti
pathogen
latter
long
histori
success
use
attack
usa
fmd
hiv
wherea
rna
virus
howev
fmd
viru
nonenvelop
picornaviru
capabl
caus
acut
diseas
persist
infect
cattl
major
constraint
trade
cloven
hoov
anim
similar
envelop
retroviru
similarli
caus
spectrum
progress
state
human
develop
mab
pathogen
gain
better
understand
humor
immun
respons
infect
gener
neutral
antibodi
use
establish
role
antibodi
protect
identifi
protect
epitop
also
facilit
vaccin
design
monoclon
antibodi
develop
directli
drive
vaccin
design
identifi
protect
antigen
vitro
vivo
correl
neutralis
biolog
effect
passiv
protect
fact
tend
preced
develop
activ
vaccin
reason
plotkin
mortim
limit
review
exampl
pathogen
relev
antibodi
develop
final
review
meant
help
scientist
decid
mab
develop
method
correct
laboratori
given
constraint
biolog
contain
fund
avail
immunogen
skill
time
detail
inform
therapeut
antibodi
reader
refer
sever
excel
review
van
dijk
van
de
winkel
gavilondo
larrick
although
mab
routin
produc
mani
year
mab
develop
without
limit
academ
scientist
produc
mab
use
rigid
qualiti
assur
protocol
develop
mab
trivial
mani
time
consum
step
necessari
produc
qualiti
antibodi
desir
characterist
quit
often
mab
develop
given
requir
financi
support
mani
commerci
compani
develop
mab
servic
fee
gener
compani
return
first
bind
clone
client
rel
low
cost
use
servic
may
worthwhil
simpl
product
mab
purifi
recombin
protein
howev
panel
mab
need
recognis
nativ
epitop
surfac
pathogen
mab
requir
biolog
function
first
ten
clone
especi
immunogen
peptid
recombin
protein
like
desir
characterist
similarli
whole
pathogen
immunogen
prepar
inher
contamin
addit
protein
cultur
unless
grown
pure
form
requir
addit
secondari
screen
furthermor
mablaboratori
addit
abil
perform
recombin
mab
clone
techniqu
greater
capac
characteris
develop
use
reagent
diagnost
purpos
therapeut
lead
scale
order
start
antibodi
develop
project
goal
object
antibodi
outlin
advanc
decis
must
made
whether
mab
necessari
polyclon
antibodi
suffic
fig
need
antibodi
recognis
nativ
organ
identifi
serolog
variant
diagnost
work
mab
develop
warrant
high
risk
pathogen
reduc
number
handl
anim
replac
vivo
requir
prepar
futur
lot
polyclon
antiserum
new
group
anim
assay
mab
sensit
polyclon
antibodi
strain
subtyp
specif
mab
definit
gener
recogn
singl
epitop
pathogen
antigen
variat
target
epitop
result
mab
unreact
serolog
variant
zhong
et
al
mani
case
polyclon
antibodi
suffici
develop
screen
assay
polyclon
antibodi
recogn
multipl
epitopeantigen
pathogen
polyclon
antibodi
crossrecognis
multipl
serolog
strain
pathogen
conserv
surfac
epitop
convers
may
distinguish
close
relat
strain
polyspecif
antibodi
also
produc
context
background
antibodi
host
anim
fig
irrelev
antibodi
caus
problem
highbackground
unwant
reactiv
contamin
antigen
prepar
use
assay
emphasis
need
highqual
purifi
immunogen
use
gener
antibodi
highqual
antigen
develop
antibodi
assay
case
exampl
fmd
viru
serotypespecif
mab
use
discrimin
serolog
reactiv
may
alway
detect
nucleic
acid
detect
system
serolog
identif
serotyp
implic
appropri
vaccin
coverag
fmd
exampl
enzym
link
immunosorb
assay
elisa
use
studi
antigen
relationship
strain
fmd
viru
fig
monoclon
polyclon
method
develop
antipathogen
antibodi
develop
polyclon
polyspecif
antiserum
complex
antigen
whole
viru
antibodi
produc
mani
antigen
viru
context
background
antibodi
reactiv
host
b
develop
polyclon
monospecif
antisera
pure
singl
compon
pathogen
antibodi
produc
singl
antigen
still
context
background
antibodi
reactiv
host
c
develop
monoclon
monospecif
antibodi
either
complex
antigen
purifi
singl
compon
pathogen
success
screen
method
develop
depend
upon
puriti
initi
immunogen
develop
hybridoma
allow
unlimit
product
pure
singl
antibodi
specif
vitro
cultur
clone
select
appropri
vaccin
kitch
et
al
vaccin
use
protect
antigen
variant
pathogen
like
fmd
viru
typespecif
ideal
strain
specif
mani
case
monospecif
polyclon
antibodi
adequ
best
choic
fig
particularli
immunogen
highli
purifi
recombin
protein
express
vivo
dna
vector
zhang
et
al
product
highli
purifi
antigen
recombin
protein
requir
work
initi
howev
polyclon
antibodi
produc
immunogen
high
qualiti
usual
low
background
reactiv
exampl
polyclon
antibodi
use
analys
larg
number
newli
discov
open
read
frame
genom
pathogen
microorgan
expens
make
mab
mani
target
may
warrant
wood
et
al
howev
monospecif
polyclon
antibodi
produc
environ
host
antibodi
antigen
produc
unwant
reactiv
subject
signific
variat
polyclon
antibodi
describ
howev
rapidli
provid
qualiti
set
reagent
set
valid
diagnost
screen
assay
monoclon
antibodi
reagent
requir
greater
invest
resourc
mab
cost
much
develop
produc
valid
stockpil
polyclon
antibodi
howev
hybridoma
line
develop
mab
made
easili
reproduc
larg
quantiti
without
lot
variat
seen
polyclon
antibodi
prepar
moreov
mab
fulli
defin
allow
mani
experi
previous
possibl
practic
use
mab
avoid
undesir
crossreact
inher
polyclon
prepar
high
affin
mab
deriv
easili
immun
anim
antigen
type
concern
assay
frequent
use
diagnost
mab
develop
approach
recommend
fig
provid
unlimit
suppli
mab
without
need
immun
anim
order
replenish
suppli
antibodi
highqual
reagent
ideal
tool
design
highthroughput
techniqu
tend
use
set
confirmatori
diagnost
test
test
relat
anim
trade
advis
intern
standard
consult
help
decid
type
reagent
produc
wright
zhou
unwant
contamin
immunogen
prepar
translat
unwant
antibodi
respons
inde
even
contamin
cell
debri
bovin
serum
albumin
bsa
stabil
fetal
bovin
serum
fb
tissu
cultur
elicit
antibodi
respons
mice
commonli
found
complex
mixtur
like
virallys
produc
tissu
cultur
contain
cell
debri
host
cell
protein
fb
pure
antigen
gradient
purifi
viru
prepar
recombin
protein
make
ideal
immunogen
essenti
high
qualiti
monoclon
polyclon
antibodi
develop
recent
experienc
import
highqual
antigen
first
hand
prepar
antibodi
reagent
sarscov
coronaviru
given
urgent
need
reagent
sarscov
sar
viru
outbreak
canada
use
polyclon
monoclon
techniqu
develop
antibodi
reagent
attempt
rapidli
produc
diagnost
antibodi
use
control
mab
develop
diagnost
assay
immun
mice
crude
sarscov
infect
vero
green
monkey
kidney
cell
line
cell
lysat
rare
use
approach
known
polyclon
ascit
techniqu
pa
laci
voss
polyclon
ascit
use
histor
product
highqual
reagent
mani
veterinari
agent
fmd
viru
pa
techniqu
produc
hightitr
antibodi
sarscov
polyclon
antibodi
gener
impur
viral
lysat
gave
unaccept
high
background
elisa
immunofluoresc
assay
ifa
immunohistochem
ihc
stain
tissu
clearli
show
contamin
host
cell
protein
immunogen
elicit
antibodi
react
directli
protein
present
sampl
use
downstream
applic
experi
went
develop
mab
gave
remain
mice
final
boost
purifi
sarscov
perform
fusion
screen
bind
use
purifi
sarscov
particl
contrast
polyclon
sera
sar
mab
develop
clearli
show
specif
sarsinfect
uninfect
host
vero
cell
fig
even
use
purifi
viru
screen
requir
reduc
initi
panel
igg
posit
clone
neg
screen
reactiv
contamin
fb
antigen
serum
free
growth
cell
infect
viru
one
way
lessen
background
effect
fb
monospecif
mab
one
advantag
produc
mab
rather
polyclon
antibodi
monospecif
inher
mab
whether
deriv
recombin
phage
select
techniqu
classic
hybridoma
fusion
two
main
method
use
today
gener
mab
classic
hybridoma
fusion
immun
antibodi
librari
fig
mice
popular
histor
mab
develop
due
product
hybridoma
deriv
mab
human
mice
rabbit
bird
receiv
attent
use
mab
librari
approach
berri
popkov
press
hybridoma
antibodi
librari
techniqu
complementari
neither
like
provid
exhaust
sampl
immun
respons
ame
et
al
krebber
et
al
inde
perhap
screen
activ
antigenspecif
primari
b
cell
come
close
reproduc
total
b
cell
respons
ex
vivo
babcook
et
al
downstream
purpos
mab
either
diagnost
research
therapeut
purpos
also
influenc
choic
method
use
gener
mab
exampl
diagnost
mab
reagent
need
antigen
abund
pure
form
direct
rout
make
hybridoma
immun
mice
depend
skill
laboratori
antigen
exceedingli
rare
purifi
antibodi
librari
capabl
neg
subtract
may
method
choic
altern
develop
mab
new
nonrod
speci
rabbit
popkov
et
al
primat
glamann
et
al
studi
anatom
distinct
immun
compart
mucos
surfac
berri
et
al
b
may
necessari
creat
recombin
antibodi
librari
design
clone
igvgen
speci
particular
isotyp
respect
lack
reliabl
myeloma
partner
prohibit
hybridoma
fusion
techniqu
widespread
use
nonrod
speci
sever
laboratori
develop
hybridoma
techniqu
nonrod
speci
rabbit
spiekerpolet
et
al
sheep
grove
et
al
cattl
grove
et
al
grove
et
al
speci
grove
morri
use
hybridoma
fusion
speci
mainli
reli
upon
heteromyeloma
fusion
partner
becom
widespread
due
low
stabil
result
clone
inde
phagemid
antibodi
librari
deriv
immun
anim
one
activ
area
phage
display
major
research
antibodi
clone
focus
upon
select
human
mab
potenti
lucr
term
market
valu
develop
human
therapeut
antibodi
optim
mab
human
origin
nonhuman
mab
gener
immun
respons
may
limit
effect
buglio
et
al
despit
advanc
mab
technolog
polyclon
immun
globulin
still
gold
standard
passiv
immunoglobulin
treatment
equin
antitoxin
human
pool
immun
globulin
still
use
develop
today
major
focu
recombin
mab
industri
produc
anticanc
mab
therapeut
develop
mab
clinic
trial
infecti
diseas
target
gavilondo
larrick
polyclon
immunoglobulin
certainli
replac
safer
fullydefin
cocktail
potent
monoclon
polyclon
antibodi
industri
develop
therapeut
mab
infecti
diseas
agent
clearli
technolog
limit
prevent
develop
mab
treatment
virtual
everi
infecti
threat
although
effect
mab
clinic
remain
empir
altern
therapeut
mab
nonhuman
primat
experiment
immun
recombin
antibodi
librari
gener
b
lymphocyt
glamann
hirsch
schofield
et
al
anoth
new
excit
altern
method
deriv
fulli
human
mab
use
hybridoma
fusion
experiment
immunis
mice
transgen
human
igvgen
jakobovit
ishida
et
al
combin
eas
simplic
hybridoma
fusion
abil
select
fulli
human
mab
hybridoma
deriv
mice
expect
meet
requir
pharmaceut
industri
new
lead
molecul
treatment
infecti
diseas
chronic
diseas
cancer
may
becom
domin
mab
technolog
purpos
provid
xenomouseproducedmab
protect
human
vivo
use
mice
also
bring
cost
product
fulli
defin
mab
cocktail
begin
replac
pool
human
equin
polyclon
sourc
strateg
partnership
provid
mechan
get
human
mab
rapidli
clinic
trial
use
help
treat
infecti
diseas
treatment
current
exist
hybridoma
remain
valuabl
raw
materi
develop
human
antibodi
therapi
rader
et
al
therapeut
mab
use
today
either
fulli
murin
human
murin
mab
vitro
modif
requir
humanis
recombin
nonhuman
mab
alter
affin
modifi
specif
select
nonimmun
mab
trivial
success
humanis
strategi
empir
entir
protein
depend
properti
origin
parent
mab
must
reproduc
human
recombin
version
case
may
possibl
difficulti
shown
fact
nearli
public
human
mab
customis
techniqu
humanis
select
strategi
passiv
antibodi
therapi
would
ideal
certain
diseas
fmd
viru
protect
afford
serum
titr
would
disappear
anim
would
serorevert
neg
statu
clearli
largescal
express
system
recombin
plant
offer
possibl
mean
product
cost
could
becom
feasibl
approach
altern
anim
made
transient
resist
certain
infect
express
protect
antibodi
specif
vivo
episom
transgen
exampl
lorenzen
et
al
gener
fish
resist
fishpathogen
rhabdoviru
vhsv
viral
haemorrhag
septicaemia
viru
appli
gene
construct
encod
neutral
singlechain
antibodi
administ
rainbow
trout
intramuscular
inject
plasmid
dna
recombin
singlechain
antibodi
express
seen
presenc
circul
recombin
antibodi
detect
fish
furthermor
protect
immun
vhsv
establish
show
mab
protect
passiv
fashion
transgen
without
alter
germlin
fish
model
infect
live
infect
model
perhap
best
way
produc
neutral
antibodi
respons
protect
epitop
infecti
pathogen
howev
mani
case
laboratori
mous
optim
anim
model
particular
infecti
diseas
case
inject
dead
antigen
may
provid
antigen
stimulu
live
replic
pathogen
anoth
anim
system
may
use
develop
mab
optim
model
nonrod
speci
recommend
use
antibodi
librari
produc
mab
b
cell
optim
host
speci
see
highli
danger
pathogen
microorgan
zoonot
pathogen
recommend
safeti
highest
consider
inactiv
pathogen
recombin
protein
use
inocul
immunogen
rather
live
pathogen
hybridoma
produc
contain
must
grown
store
contain
new
emerg
diseas
reliabl
start
point
use
hybridoma
fusion
mice
immunis
best
immunogen
possibl
whether
one
use
hybridoma
fusion
immun
antibodi
librari
technolog
fundament
reli
upon
host
immun
system
immunogensensit
b
cell
suitabl
screeningselect
system
must
develop
ahead
time
hybridoma
recombin
antibodi
librari
respect
hybridoma
system
must
place
time
hybridoma
readi
screen
hybridoma
clone
need
cultur
screen
subclon
store
quickli
die
neglect
essenti
mean
singl
opportun
screen
panel
hybridoma
clone
within
narrow
window
time
cultur
continu
expand
becom
difficult
handl
howev
immun
antibodi
librari
time
avail
develop
select
screen
assay
igvgen
clone
librari
optim
mab
librari
store
indefinit
plasmid
reamplifi
repeatedli
screen
new
antigen
prepar
provid
anim
also
immun
target
schofield
et
al
schofield
et
al
b
lymphocyt
pool
constant
state
flux
immunogenspecif
lymphocyt
respons
limit
clonal
select
avail
b
cell
pool
compris
newli
emerg
antigen
b
cell
antigen
activ
plasmablast
memori
b
cell
berek
milstein
size
avail
antibodi
repertoir
b
cell
per
mous
immun
anim
b
cell
pool
becom
greatli
enrich
specif
binder
via
clonal
expans
repeat
exposur
occur
natur
follow
antigen
challeng
host
immun
system
immunogen
mani
b
cell
initi
trigger
exposur
antigen
becom
limit
b
cell
select
process
take
place
mainli
germin
centr
immun
mice
estim
somewher
antigen
specif
b
cell
gener
respons
complex
antigen
whole
viru
bachmann
et
al
howev
success
mab
develop
depend
upon
adequ
sampl
sensit
b
cell
screen
antibodi
produc
experiment
immun
anim
import
sampl
b
cell
pool
respons
wax
spleen
excel
sourc
activ
b
cell
mice
exampl
spleen
immun
adult
mous
compris
b
cell
make
immun
spleen
ideal
either
immun
antibodi
librari
gener
hybridoma
product
thompson
cancro
rigor
evalu
hybridoma
form
neither
preplasma
plasmablast
cell
instead
antigenactiv
prolifer
b
lymphocyt
blast
fuse
myeloma
becom
hybridoma
guoliang
et
al
b
lymphocyt
blast
cell
predomin
murin
spleen
day
booster
inject
bazin
lemieux
fig
b
time
frame
becom
protract
antigen
deliveri
system
adjuv
dna
vaccin
recombin
live
viral
vector
jdb
person
observ
reason
mab
develop
recommend
final
booster
fusion
collect
rna
deliv
salin
either
intraven
intraperiton
simultan
sourc
tissu
critic
mab
gener
previous
immun
human
circul
memori
b
cell
antigen
specif
within
day
booster
immunis
nanan
et
al
howev
blood
dilut
sourc
b
cell
limit
number
activ
b
cell
present
thu
blood
optimum
sourc
lymphocyt
gener
recombin
antibodi
librari
hybridoma
yip
et
al
tissu
rich
antigen
specif
plasmablast
bone
marrow
drain
lymph
node
spleen
ideal
gener
hybridoma
antibodi
librari
provid
adequ
sampl
antigenspecif
b
cell
lymph
node
larg
anim
even
cervic
lymphocyt
collect
swab
human
serv
success
b
cell
sourc
immun
antibodi
librari
et
al
berri
et
al
b
detail
studi
complet
plasmablast
stage
thought
use
immun
librari
gener
cell
contain
time
specif
ig
mrna
rest
b
cell
yuan
tucker
lefkovit
fulli
differenti
antigen
activ
plasmablast
cell
rapidli
appear
presensit
anim
follow
recal
respons
indic
elev
specif
igg
serum
titr
day
fig
method
use
produc
monoclon
antibodi
affect
repres
mab
discov
bias
inher
recombin
antibodi
librari
includ
pcr
amplif
clone
bia
amplif
restrict
digest
bacteri
express
foldingtox
escherichia
coli
host
although
histor
controversi
issu
clear
ident
monoclon
antibodi
isol
antigen
use
either
hybridoma
antibodi
librari
howev
may
rare
find
without
exhaust
comparison
molecular
sequenc
immunoglobulin
vgene
antigen
specif
mab
reveal
system
appear
captur
similar
yet
distinct
repres
crosssect
b
cell
respons
ohlin
borrebaeck
caton
koprowski
duggan
et
al
gherardi
milstein
kettleborough
et
al
ame
et
al
studi
comprehens
vastli
differ
properti
immunogen
use
exampl
make
difficult
directli
compar
molecular
genet
antibodi
recov
whole
virus
versu
highli
conserv
cytokin
protein
thu
mab
discoveri
method
inher
bias
result
uniqu
cross
sampl
repertoir
mab
obtain
immun
anim
fig
b
outlin
gener
flow
produc
mab
immun
librari
compar
hybridoma
product
follow
recombin
clone
method
adapt
modern
highthroughput
method
clone
pick
screen
stage
hybridoma
produc
immortalis
b
cell
express
antigenspecif
immunoglobulin
fig
hybrid
cell
line
made
fuse
immort
myeloma
cell
tumor
cell
shortliv
primari
b
cell
immun
rodent
b
cell
kohler
milstein
drug
select
screen
supernat
produc
hybrid
cell
hybridoma
identifi
antigen
reactiv
cell
line
produc
antibodi
desir
properti
stabl
clone
expand
cell
scaledup
antibodi
product
recommend
modifi
direct
fusion
clone
method
semisolid
methyl
cellulosehat
contain
media
davi
et
al
appropri
media
supplement
modern
descript
hybridoma
fusion
method
reader
direct
follow
protocol
berri
ranada
singl
foci
cell
grow
becom
visibl
eye
transfer
well
plate
expans
screen
supernat
mani
case
elisa
base
method
use
identifi
antigen
specif
clone
altern
subclon
hybridoma
posit
well
limit
dilut
anoth
mean
obtain
clonal
cultur
fazeka
de
st
groth
scheidegg
fazeka
de
st
groth
spira
et
al
although
labori
expand
antigen
specif
hybridoma
cell
cultur
flask
singl
cell
possibl
produc
clonal
popul
cell
produc
singl
specif
antibodi
hybridoma
techniqu
routin
use
commerci
compani
develop
mab
research
diagnost
tool
hybridoma
procedur
quit
robust
rodent
tradit
effici
mean
produc
monoclon
antibodi
date
ten
thousand
clone
develop
sinc
michaud
et
al
monospecif
reactiv
variou
antigen
offer
mani
qualiti
compani
remark
mani
well
known
infecti
agent
mab
reagent
yet
exist
newli
emerg
infecti
diseas
requir
mab
develop
capac
maintain
howev
despit
recent
advanc
establish
new
myeloma
partner
variou
speci
grove
morri
hybridoma
reliabl
produc
nonrod
mab
nonrod
hybridoma
fusion
murin
myeloma
still
use
robust
growth
tumorlik
properti
allow
singl
cell
clone
moreov
cell
necessari
cellular
machineri
antibodi
product
b
cell
tumour
match
correct
mhcbackground
myeloma
result
hybridoma
seen
immun
system
foreign
cell
toler
therefor
suitabl
ascit
product
import
keep
hybridoma
grow
rapidli
screen
phase
multipl
level
screen
requir
narrow
panel
clone
kept
aliv
tissu
cultur
possibl
stop
store
primari
b
cell
revisit
futur
without
huge
loss
viabil
done
librari
recombin
antibodi
stabl
longer
term
clone
phagemid
hybridoma
fusion
requir
intens
period
laboratori
activ
week
post
fusion
screen
begin
mani
case
simpl
elisa
dotblot
set
primari
screen
clone
posit
round
movedup
well
plate
subject
second
test
neg
screen
may
requir
remov
clone
reactiv
contamin
test
usual
becom
select
specif
util
intend
downstream
applic
reduc
panel
number
exampl
secondari
screen
may
whole
organ
verifi
reactiv
develop
mab
sarscov
elisa
test
initi
use
screen
ihc
follow
ifa
western
immunoblot
final
viru
neutralis
assay
mani
common
tertiari
screen
also
use
similar
confirmatori
diagnost
assay
hybridoma
fusion
limit
drawback
hybridoma
develop
includ
fusion
larg
limit
splenic
b
cell
rodent
chemic
fusion
process
random
although
immun
anim
overwhelm
bia
antigen
specif
b
cell
infer
rise
serum
igg
titr
difficult
produc
antibodi
complex
mixtur
tissu
cultur
becom
expens
term
media
reagent
fb
convers
advantag
hybridoma
methodolog
includ
technolog
simplic
highli
effici
reliabl
hybridoma
still
main
choic
research
diagnost
mab
produc
commerci
avail
mab
hybridoma
provid
full
length
glycosyl
mab
use
epitop
map
studi
vivo
model
hybridoma
provid
unlimit
suppli
antibodi
requir
simpl
cultiv
purif
gener
homogen
prepar
cost
produc
mab
hybridoma
reduc
use
serumfre
cultur
scaleup
lastli
screen
biolog
activ
exampl
viru
toxin
neutralis
may
perform
relev
usual
done
subsequ
primari
assay
bind
order
reduc
size
panel
screen
usual
complex
bioassay
case
biolog
screen
use
primari
screen
may
result
complet
absenc
posit
clone
may
antigen
specif
clone
may
bioactiv
mani
nonneutr
import
diagnost
research
mab
develop
variou
epitop
envelop
protein
siv
simian
immunodefici
viru
kent
et
al
akerblom
et
al
respect
well
epitop
protein
fmd
viru
barnett
et
al
butchaiah
morgan
hybridomaderiv
mab
would
identifi
would
avail
today
research
diagnost
tool
primari
screen
bioactiv
antibodi
librari
produc
immun
repertoir
repres
altern
mean
mab
produc
today
rader
techniqu
depend
upon
abil
recov
express
immunoglobulin
repertoir
recover
b
lymphocyt
rna
construct
repres
antibodi
variabl
region
gene
vgene
cdna
librari
display
function
fragment
select
antigen
sourc
hybridoma
technolog
reli
upon
immortalis
antigen
specif
b
cell
recombin
antibodi
made
immortalis
cdna
encod
immunoglobulin
gene
fig
first
select
neutral
human
monoclon
antibodi
fragment
infecti
agent
combinatori
antibodi
librari
respiratori
syncyti
viru
barba
et
al
b
respect
excel
recent
paper
publish
develop
recombin
mab
potenti
agent
bioterror
reader
refer
gao
et
al
hayhurst
et
al
repertoir
clone
librari
select
mab
base
upon
molecular
sequenc
gene
encod
immunoglobulin
vgene
particular
speci
thu
antibodi
librari
depend
upon
random
immortalis
clone
antibodi
produc
lymphocyt
case
hybridoma
instead
nucleotid
sequenc
vgene
use
design
oligonucleotid
primer
reversetranscriptas
base
pcr
clone
end
upstream
vgene
correspond
framework
much
conserv
less
variabl
complementar
determin
region
cdr
encod
antigen
contact
site
paratop
therefor
knowledg
vgene
sequenc
compris
predomin
vgene
b
cell
pool
given
speci
allow
design
set
upstream
primer
oligonucleotid
antibodi
librari
use
select
mab
virtual
speci
long
vgene
variabl
region
gene
respons
encod
antigen
contact
domain
clone
therefor
recombin
antibodi
librari
depend
upon
vgene
rather
b
cell
phage
antibodi
techniqu
use
gener
mab
wide
spectrum
speci
berri
popkov
press
filament
phagedisplay
develop
display
polypeptid
earli
smith
follow
seri
experi
demonstr
abil
affin
select
solvent
expos
polypeptid
ligand
parmley
smith
linkag
genotyp
phenotyp
first
select
phage
peptid
display
librari
publish
use
peptid
ligand
express
upon
surfac
fphage
scott
smith
devlin
et
al
cwirla
et
al
discoveri
collect
led
develop
mani
type
recombin
antibodi
librari
discuss
detail
elsewher
andriswidhopf
et
al
primer
set
clone
immunoglobulin
repertoir
speci
uniqu
gener
structur
immunoglobulin
vgene
conserv
murin
vgene
classifi
group
call
famili
base
upon
homolog
higher
germlin
level
kofler
et
al
similar
terminolog
adopt
describ
vgene
speci
antibodi
librari
reli
upon
integr
nucleic
acid
encod
specif
domain
protein
cdna
produc
store
indefinit
futur
repeat
analysi
mani
antibodi
librari
display
format
use
berri
popkov
press
phage
phagemid
use
display
scfv
mccafferti
et
al
fab
clackson
et
al
combinatori
fab
scfv
immun
antibodi
librari
burton
barba
phagemid
librari
phenotyp
mix
e
coli
host
coinfect
helper
phage
result
assembl
fulli
infecti
phage
particl
eukaryot
prokaryot
ribosom
display
system
also
use
deriv
mab
taussig
hane
pluckthun
respect
vitro
link
transcript
translat
system
ribosom
display
wide
use
compar
tradit
phage
display
like
becom
use
routin
mab
develop
small
research
laboratori
sever
uniqu
advantag
use
antibodi
librari
recombin
antibodi
clone
includ
abil
clone
express
isotyp
specif
librari
select
specif
class
mab
includ
iga
moreno
de
alboran
et
al
berri
et
al
ige
class
steinberg
et
al
altern
isotyp
either
select
librari
made
nonigg
class
specif
back
primer
correspond
isotyp
mab
reconstruct
particular
class
clone
appropri
constant
domain
wolbank
et
al
inde
mab
develop
via
either
hybridoma
antibodi
librari
recombin
antibodi
method
use
rapidli
convert
select
bind
fragment
full
length
antibodi
human
isotyp
vitro
boel
et
al
antibodi
librari
affinityselect
bind
clone
librari
mere
screen
bind
activ
select
process
progress
enrich
bind
clone
abil
rescreen
recombin
antibodi
librari
possibl
freez
librari
cdna
screen
futur
antibodi
display
librari
neg
subtract
irrelev
nontarget
background
protein
help
enrich
mab
receptor
complex
recombin
antibodi
librari
well
suit
mani
downstream
molecular
approach
vitro
affin
improv
recombin
antibodi
librari
allow
mab
develop
speci
recombin
system
amen
develop
faster
higherthrough
put
screen
antibodi
librari
strategi
appear
streamlin
mab
develop
process
save
time
need
immun
anim
setup
immun
librari
predict
increas
number
commerci
mab
develop
strategi
move
toward
use
larg
recombin
librari
de
wildt
et
al
well
synthet
singlescaffold
system
soderlind
et
al
phage
ribosom
display
format
although
librari
may
limit
high
affin
binder
howev
smaller
research
laboratori
larg
scale
techniqu
may
cost
time
although
mani
mab
select
librari
mab
gener
lower
affin
mab
empir
qualiti
must
test
individu
biolog
activ
cross
reactiv
especi
low
affin
movement
toward
highthroughput
mab
develop
industri
increas
import
smaller
dedic
mabfacil
develop
high
affin
biolog
relev
mab
medic
veterinari
infecti
diseas
research
limit
recombin
mab
develop
includ
technolog
challeng
develop
approach
gener
less
robust
hybridoma
method
repeat
select
must
perform
novic
area
recombin
antibodi
fragment
produc
fab
scfv
fulllength
glycosyl
mab
requir
eukaryot
vector
genet
clone
fc
portion
variabl
fragment
product
e
coli
express
mab
fragment
empir
lp
contamin
still
necessari
screen
clone
biolog
activ
may
well
difficult
target
common
bacteri
antigen
exampl
lp
outer
conserv
bacteri
outer
membran
protein
e
coli
base
phage
display
randomis
v
h
v
l
pair
even
success
enrich
bind
clone
may
end
contamin
bsa
stabil
reason
antibodi
librari
method
commonli
use
gener
diagnost
research
antibodi
immun
librari
product
mab
valuabl
studi
antibodi
divers
fundament
studi
antibodi
gene
divers
usual
preced
use
new
speci
antibodi
librari
develop
antibodi
librari
use
examin
repertoir
cattl
ig
sinclair
aitken
sinclair
et
al
primat
ehrlich
et
al
xenopu
hsu
et
al
sheep
dufour
et
al
pathogen
specif
molecular
profil
antibodi
respons
human
examin
comprehens
antibodi
librari
barba
et
al
abil
analys
multipl
compon
antibodi
respons
particular
recombin
gene
express
individu
mab
even
particular
isotyp
ad
greatli
understand
antibodi
respons
develop
matur
moreov
knowledg
vgene
sequenc
exploit
develop
highthroughput
recombin
clone
method
mab
develop
use
robot
equip
de
wildt
et
al
hybridoma
cell
line
repres
excel
resourc
gener
recombin
human
chimer
mab
therapeut
develop
biothreat
agent
nathan
et
al
deng
et
al
mani
laboratori
valuabl
hybridoma
cell
line
highrisk
pathogen
addit
diagnost
valu
excel
foundat
recombin
mab
program
revers
transcriptas
pcr
clone
vgene
hybridoma
serv
introduc
scientist
recombin
antibodi
technolog
mani
excel
paper
produc
optimis
pcr
clone
vgene
human
murin
hybridoma
use
pcr
good
sourc
primer
sequenc
larrick
et
al
b
orlandi
et
al
gavilondocowley
et
al
dattamajumdar
et
al
reader
direct
upcom
book
chapter
comprehens
summari
minim
primer
par
use
amplifi
vgene
speci
use
antibodi
librari
berri
popkov
press
key
issu
phageantibodi
librari
develop
decis
use
specif
plasmid
base
dna
vector
impact
upon
subsequ
primer
design
clone
sequenc
vgene
valuabl
hybridoma
provid
precis
molecular
characteris
bind
domain
import
downstream
recombin
modif
fundament
immunolog
tabl
antigen
scale
work
upfront
develop
recombin
protein
bind
recombin
protein
guarante
bind
nativ
protein
pair
recombin
purifi
fusion
protein
eg
pmalproteinx
immun
pgexprotein
x
screen
pari
fusion
protein
remov
background
mab
immunogen
fusion
protein
target
nativ
structur
whole
microb
work
upfront
develop
two
fusion
protein
gradient
protocol
work
stream
determin
ident
target
molecul
complex
antigen
whole
microb
peptidecarri
immunogen
nativ
organ
antigen
target
nativ
stuructur
whole
microb
produc
maney
mab
irrelev
contamin
must
imak
neg
select
librari
screen
hybridoma
bind
peptid
guarante
bind
nativ
protein
antibodi
librari
proprietari
purpos
bind
domain
uniqu
ident
inher
vgene
inde
abil
clone
antigenbind
specif
given
hybridoma
clone
recombin
dna
lead
free
exchang
hybridoma
cell
line
immortalis
uniqu
specif
mab
lastli
clone
specif
hybridoma
crucial
rescu
vdomain
extrem
valuabl
hybridoma
line
act
independ
specif
guard
catastroph
loss
mab
predict
increas
use
recombin
antibodi
librari
develop
mab
speci
veterinari
import
wide
spectrum
fit
among
immunogen
term
eas
develop
mab
gener
characterist
immunogenantigen
pair
use
mab
develop
strategi
allow
us
crude
classifi
mab
develop
strategi
base
expect
outcom
term
success
defin
letter
scale
better
gaug
expect
outcom
tri
produc
mab
particular
purpos
tabl
letter
scale
rang
c
amic
b
bruteforc
c
challeng
reflect
overal
probabl
success
basic
strategi
antigen
scale
affect
inher
immunogen
class
immunogen
antigen
call
immunogen
use
rais
antibodi
respons
good
immunogen
produc
antibodi
recognis
correspond
whole
organ
nativ
nondenatur
form
terminolog
use
often
subunit
vaccin
synthet
recombin
dna
compris
express
antigen
intend
portray
protect
antigenepitop
pathogen
strategi
repres
simplest
case
mab
easili
develop
via
hybridoma
fusion
screen
exampl
mab
need
recognis
recombin
protein
protein
use
immunogen
antigen
includ
express
protein
vivo
episom
mab
develop
barri
et
al
contamin
protein
bacteri
plasmid
prepar
stabil
present
commerci
protein
must
kept
mind
recommend
special
purif
use
remov
request
special
order
commerci
compani
without
stabil
gel
purifi
express
plasmid
prior
inject
convers
mab
strategi
c
challeng
class
may
reflect
need
use
subtract
screen
exceedingli
rare
antigen
tempor
constraint
hybridoma
develop
target
fall
middl
categori
requir
brute
forc
approach
strategi
b
type
b
strategi
mab
possibl
via
hybridoma
fusion
howev
sever
attempt
method
develop
may
requir
order
obtain
clone
choic
although
everi
target
present
uniqu
challeng
provid
gener
exampl
mab
develop
origin
investig
antigen
fall
categori
tabl
bind
mab
guarante
biolog
activ
antigen
scale
complet
reflect
immunogen
given
immunogen
empir
discov
test
addit
may
simpl
develop
monoclon
antibodi
particular
immunogen
mani
case
antibodi
may
desir
bind
characterist
bioactiv
exampl
simpl
creat
antipeptid
mab
use
peptidecarri
combin
situat
could
classifi
type
howev
use
peptidecarri
immunogen
tri
creat
mab
react
recombin
protein
would
shift
type
b
mab
strategi
recombin
protein
alway
fold
epitop
access
bind
would
discov
inabl
mab
bind
form
recombin
protein
denatur
protein
one
step
use
peptidecarri
immunogen
tri
develop
mab
bind
nativ
protein
virion
exampl
may
class
type
c
mab
strategi
antigen
scale
assur
antipeptid
mab
recognis
nativ
protein
contain
correspond
peptid
epitop
context
whole
organ
moreov
assur
biolog
activ
even
antibodi
produc
bind
nativ
organ
trudel
et
al
joyc
et
al
exampl
nonneutr
human
mab
murin
leukaemia
viru
bound
virion
affin
similar
neutral
mab
indic
epitop
exposur
necessari
suffici
case
viral
neutralis
vitro
burkhart
et
al
thu
easi
underestim
difficulti
associ
product
highqual
mab
date
method
link
abil
select
bind
clone
bioassay
involv
pathogen
panel
mab
must
still
first
identifi
bind
properti
molecul
must
test
biolog
activ
independ
assay
mani
factor
influenc
success
develop
mab
microorgan
two
critic
factor
puriti
dose
immunogen
factor
site
number
inject
use
adjuv
influenc
immun
respons
somewhat
less
critic
antigen
impur
dose
low
may
nearli
imposs
screen
good
bind
clone
quantit
measur
immunogen
help
gaug
probabl
success
best
clone
kept
empir
determin
antigen
depend
upon
properti
antigen
hybridoma
clone
includ
isotyp
igg
predominantli
kept
level
express
antigen
coat
screen
elisa
paramet
use
od
greater
h
greater
equal
dilut
supernat
c
posit
influenc
factor
includ
final
booster
screen
perform
gradient
purifi
virion
factor
shift
rate
antigen
b
posit
influenc
factor
includ
highli
purifi
synthet
carbohydr
cho
attach
tcell
epitop
rich
carrier
protein
unconjug
cho
use
antigen
screen
elisa
remov
mab
carrier
protein
factor
shift
rate
antigen
c
cho
usual
difficult
antigen
produc
mab
e
neg
influenc
factor
includ
gener
mab
peptiderec
protein
screen
crossreact
nativ
antigenorgan
shift
antigen
scale
rate
b
even
c
f
sum
final
inject
total
inject
analyt
assess
immunogen
use
sdspage
massspectrometri
similar
techniqu
suggest
prior
immunis
anim
strongli
encourag
extra
prepar
time
taken
produc
highqual
pure
immunogen
use
immunostimul
adjuv
improv
inflamm
inject
site
use
agent
recommend
improv
b
cell
respons
weak
immunogen
adjuv
also
improv
respons
passeng
contamin
thu
puriti
paramount
mani
rapid
immunis
method
develop
berri
et
al
herein
provid
basic
immunis
strategi
hybridoma
fusion
mice
total
recombin
protein
typic
condit
mg
purifi
protein
optim
mg
protein
immunis
mg
screen
administ
fourto
five
inject
lg
purifi
total
protein
per
mous
per
dose
anoth
method
measur
dose
base
upon
infecti
load
prior
pathogen
inactiv
exampl
load
infecti
unit
plaqu
form
unit
live
materi
prior
inactiv
suffici
dose
per
inject
provid
materi
rel
pure
still
anoth
measur
viralparticl
count
use
electron
microscopi
case
particl
per
inject
approxim
equival
dose
valu
gener
guidelin
work
well
hand
exampl
factor
provid
posit
effect
success
includ
good
techniqu
qualiti
control
highli
train
technic
staff
purifi
immunogen
inject
antigen
screen
neg
influenc
includ
poor
techniqu
inexperi
impur
immunogen
andor
antigen
fb
cell
debri
use
differ
immunogen
immunis
screen
step
eg
immun
synthet
recombin
immunogen
screen
whole
viru
antigen
two
seriou
consider
mab
develop
highli
infecti
pathogen
immunogen
purityconform
directli
relat
method
inactiv
pathogen
nativ
organ
alway
ideal
immunogen
adequ
purifi
panel
mab
complex
antigen
mixtur
whole
bacterium
requir
downstream
work
secondari
screen
order
determin
molecul
target
western
immunoblot
immunoprecipit
etc
complic
deal
biocontain
level
organ
must
first
inactiv
brought
contain
level
mab
product
less
valu
hybridoma
develop
within
level
contain
space
hybridoma
never
remov
live
cell
line
remov
contain
hybridoma
rna
encod
specif
mab
safe
remov
protein
denatur
strong
chemic
guanidium
isothiocyan
commonli
use
harvest
rna
recombin
mab
product
safeti
consider
asid
pathogen
inactiv
import
consider
success
mab
develop
mab
recognis
immunogen
live
pathogen
optim
inactiv
process
alter
avail
andor
conform
epitop
surfac
pathogen
particular
heat
strong
denatur
urea
use
simpl
test
reactiv
immun
sera
anim
nativ
organ
contain
perform
sacrif
anim
serum
igg
reactiv
serum
mous
use
hybridoma
fusion
clearli
littl
chanc
isol
mab
react
nativ
organ
sometim
requir
develop
mab
specif
molecul
within
complex
mixtur
exampl
protect
membran
protein
upon
surfac
bacterium
zhang
et
al
creat
new
difficulti
especi
target
immunodomin
mab
produc
domin
antigen
mani
b
cell
initi
activ
presenc
invad
pathogen
clonal
select
ensur
highest
affin
b
cell
prevail
classic
antigen
competit
occur
among
complex
antigen
exampl
bacterium
e
coli
hammerl
et
al
circumv
use
subunit
immunogen
avail
recombin
subunit
antigen
mab
develop
invalu
infecti
diseas
research
recombin
antigen
singl
toxin
subunit
safe
use
level
condit
outsid
contain
must
individu
evalu
abil
maintain
nativ
structur
use
immunogen
case
integr
membran
protein
readili
portray
recombin
protein
case
individu
subdomain
protein
synthet
peptid
correspond
expos
region
may
use
immunogen
although
must
verifi
immunogen
case
recombin
protein
make
excel
immunogen
gener
mab
less
domin
target
exampl
fmdv
surfac
tabl
whole
fmdv
use
immunogen
portion
total
b
cell
respons
direct
howev
recombin
purifi
use
immunogen
entir
b
cell
respons
direct
epitop
secondari
screen
whole
fmdv
perform
select
surfac
expos
epitop
altern
exampl
hybridoma
fusion
antibodi
librari
utilis
antibodi
mask
domin
epitop
order
develop
mab
recess
target
gani
et
al
ditzel
et
al
respect
potenti
method
alter
immunodomin
epitop
includ
mask
nlink
carbohydr
garriti
et
al
cationis
anion
side
chain
altmann
sequenti
immunis
antigen
variant
reev
et
al
dendrit
cell
immunotarget
berri
et
al
toler
golumbeski
dimond
hockfield
william
et
al
lebron
et
al
mani
applic
mab
infecti
diseas
research
develop
diagnost
trade
therapi
common
applic
includ
research
tool
cell
antigen
pathogen
identif
pathogenesi
studi
ligand
column
chromatographi
molecul
purif
diagnost
reagent
therapeut
antibodi
prepar
identif
protect
antigensepitop
vaccin
develop
addit
mani
procedur
mab
use
basic
scienc
laboratori
includ
sever
exampl
illustr
util
mab
diagnost
research
develop
exampl
identifi
sarscov
infect
vero
cell
immunohistochem
stain
mycoplasma
mycoid
subspeci
mycoid
thin
section
immunoem
intracellular
infect
human
hela
cell
chlamydia
confoc
imag
mab
bind
oblig
intracellular
eubacteri
pathogen
chlamydia
trachomati
mous
pneumon
infect
hela
cell
monolay
case
mab
directli
conjug
fitc
use
stain
methanol
fix
monolay
bright
field
shown
comparison
intracellular
inclus
western
immunoblot
anthrax
toxin
mab
b
pa
anthrax
protect
antigen
pa
trypsin
treat
pa
toxin
jdb
manuscript
prepar
flow
cytometri
depict
bind
recombin
human
mab
mab
stain
hela
cell
express
blue
fill
normal
hela
cell
red
line
trachomati
use
ifa
western
immunoblot
pa
toxin
bacillu
anthraci
recombin
human
mab
recognit
cell
express
fig
immunoelectron
microscopi
iem
particularli
valuabl
techniqu
pathogen
identif
direct
reader
excel
review
applic
iem
emerg
bioterror
agent
use
rapidli
identifi
pathogen
hazelton
gelderblom
morpholog
virion
spore
bacterium
easili
resolv
use
electron
microscopi
combin
qualiti
mab
reagent
gener
power
tool
confirmatori
diagnost
procedur
fig
iem
use
identifi
ultrastructur
bind
thin
section
rapid
protocol
demonstr
surfac
immunostain
role
antibodi
constant
region
key
function
determin
sever
effector
role
antibodi
gener
igg
class
mab
desir
due
high
specif
low
crossreact
usual
affin
matur
class
antibodi
similarli
cregion
inappropri
mab
less
like
function
vivo
limit
therapeut
valu
monoclon
antibodi
desir
constant
region
isotyp
obtain
use
classspecif
secondari
reagent
recognis
specif
constant
domain
eg
fcc
use
primer
amplifi
desir
isotyp
moreno
de
alboran
et
al
steinberg
et
al
berri
et
al
hybridoma
immun
librari
respect
critic
import
scientist
abl
exploit
complementari
techniqu
hybridoma
fusion
recombin
antibodi
librari
mab
develop
use
larg
scale
express
system
transspeci
ig
transgen
anim
highthroughput
system
increas
greatli
next
decad
crucial
govern
academ
train
institut
develop
sustain
suitabl
strategi
ensur
adequ
avail
train
staff
skill
tissu
cultur
recombin
mab
develop
techniqu
anticip
phage
librari
strategi
use
murin
vgene
hybridoma
combin
immun
repertoir
xenomic
easi
way
swap
antigen
specif
human
immunoglobulin
chain
given
specif
addit
explos
growth
predict
nonrod
mab
develop
conceiv
genet
engin
mice
encod
vgene
larg
anim
speci
develop
futur
veterinari
use
strategi
ration
approach
reagent
immunoassay
develop
need
help
ensur
protect
livestock
public
health
protect
front
line
respond
war
fighter
